Related Experiment Video

Updated: Aug 18, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

535

Anti-angiogenic Drug Resistance: Roles and Targeting of Non-coding RNAs (microRNAs and long non-coding RNAs)

Masoumeh Eliyasi Dashtaki1, Sorayya Ghasemi2

  • 1Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.

Current Molecular Pharmacology
|December 7, 2022
PubMed

Insights

Non-coding RNAs (ncRNAs) drive resistance to anti-angiogenesis cancer drugs. Targeting these ncRNAs offers new strategies for effective cancer treatment and monitoring drug response.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancers with high angiogenesis are challenging to treat, with anti-angiogenesis drugs being a primary therapy.
  • Intrinsic or acquired resistance to anti-angiogenesis drugs limits clinical efficacy.
  • Non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), play a critical role in cancer drug resistance.

Approach:

  • This review elucidates the mechanisms of anti-angiogenic drug resistance.
  • It details the involvement of dysregulated ncRNAs (miRNAs, lncRNAs) in resistance.
  • Signaling pathways influenced by these ncRNAs in response to anti-angiogenic drugs are explored.

Key Points:

  • ncRNA dysregulation significantly impacts anti-angiogenic drug resistance.
  • ncRNAs are potential therapeutic targets for overcoming resistance and inhibiting tumor angiogenesis.
  • Specific ncRNAs can serve as biomarkers for predicting anti-angiogenic drug response and non-invasive cancer monitoring.

Conclusions:

  • Targeting ncRNAs presents a promising strategy to overcome anti-angiogenic drug resistance.
  • Combination therapies involving anti-angiogenesis drugs and ncRNA-targeting agents may enhance treatment outcomes.
  • Future research directions include developing novel anti-angiogenic drugs that target specific ncRNAs implicated in resistance.
Keywords:
Angiogenesisanti-angiogenic drugscancer therapiesdrug resistancemicro-RNAsnon-coding RNAs

More Related Videos

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.5K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K